<SEC-DOCUMENT>0000950170-24-103100.txt : 20240904
<SEC-HEADER>0000950170-24-103100.hdr.sgml : 20240904
<ACCEPTANCE-DATETIME>20240904071013
ACCESSION NUMBER:		0000950170-24-103100
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20240904
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240904
DATE AS OF CHANGE:		20240904

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Invivyd, Inc.
		CENTRAL INDEX KEY:			0001832038
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				851403134
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40703
		FILM NUMBER:		241275850

	BUSINESS ADDRESS:	
		STREET 1:		1601 TRAPELO ROAD
		STREET 2:		SUITE 178
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02451
		BUSINESS PHONE:		(781) 819-0080

	MAIL ADDRESS:	
		STREET 1:		1601 TRAPELO ROAD
		STREET 2:		SUITE 178
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02451

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Adagio Therapeutics, Inc.
		DATE OF NAME CHANGE:	20201112
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ivvd-20240904.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2024-09-03T17:33:41.3722+00:00 -->
<!-- Copyright (c) 2024 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ivvd="http://invivyd.com/20240904" xmlns:calc="https://xbrl.org/2023/calculation-1.1" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:utr="http://www.xbrl.org/2009/utr">
 <head>
  <title>8-K</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_cf9258cb-0d80-48de-a3a4-1de84b58c544" name="dei:AmendmentFlag" contextRef="C_ee8b611c-368b-4b8c-a1ac-449d6289aa0e" format="ixt:fixed-false">false</ix:nonNumeric><ix:nonNumeric id="F_8623cbe1-96f9-474f-9f72-079429d958e3" name="dei:EntityCentralIndexKey" contextRef="C_ee8b611c-368b-4b8c-a1ac-449d6289aa0e">0001832038</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="ivvd-20240904.xsd"/></ix:references><ix:resources><xbrli:context id="C_ee8b611c-368b-4b8c-a1ac-449d6289aa0e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832038</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-09-04</xbrli:startDate><xbrli:endDate>2024-09-04</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">UNITED STATES</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">WASHINGTON, D.C. 20549</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;border-bottom:1pt solid #000000;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">FORM </span><span style="font-size:18pt;font-family:Times New Roman;"><ix:nonNumeric id="F_143f54b2-1deb-4552-a6a4-a3e61dd4602e" contextRef="C_ee8b611c-368b-4b8c-a1ac-449d6289aa0e" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">8-K</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;border-bottom:1pt solid #000000;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">CURRENT REPORT</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to Section 13 or 15(d)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">of the Securities Exchange Act of 1934</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Date of report (Date of earliest event reported): </span><span style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c3a64289-26a5-4713-833e-432f94fe9639" contextRef="C_ee8b611c-368b-4b8c-a1ac-449d6289aa0e" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">September 4, 2024</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;border-bottom:1pt solid #000000;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:24pt;font-family:Times New Roman;"><ix:nonNumeric id="F_757c114b-1823-41a1-8588-3e7440648c09" contextRef="C_ee8b611c-368b-4b8c-a1ac-449d6289aa0e" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:24pt;font-family:Times New Roman;min-width:fit-content;">Invivyd, Inc.</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(Exact Name of Registrant as Specified in its Charter)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;border-bottom:1pt solid #000000;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:34.58%;"/>
    <td style="width:1%;"/>
    <td style="width:30.78%;"/>
    <td style="width:3.8%;"/>
    <td style="width:29.84%;"/>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_1f0054b3-ff26-4b0f-9ee1-735b33f484c9" contextRef="C_ee8b611c-368b-4b8c-a1ac-449d6289aa0e" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_96edda8a-8f73-4e57-b549-ce8bf2a90843" contextRef="C_ee8b611c-368b-4b8c-a1ac-449d6289aa0e" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">001-40703</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_7ba1cddb-0dd9-4ad4-8a40-e242f9e45c6c" contextRef="C_ee8b611c-368b-4b8c-a1ac-449d6289aa0e" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">85-1403134</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(State or Other Jurisdiction</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">of Incorporation)</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Commission</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">File Number)</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(IRS Employer</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Identification No.)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:49.04%;"/>
    <td style="width:9.62%;"/>
    <td style="width:41.34%;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_a45ec0d3-c526-4f70-9d5c-8d8a32584ebf" contextRef="C_ee8b611c-368b-4b8c-a1ac-449d6289aa0e" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">1601 Trapelo Road</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">, </span><span><ix:nonNumeric id="F_97225d7c-5297-441c-9f2b-e0122b7c1b60" contextRef="C_ee8b611c-368b-4b8c-a1ac-449d6289aa0e" name="dei:EntityAddressAddressLine2"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Suite 178</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span><ix:nonNumeric id="F_1b00c894-2915-410e-9f53-43e248a829cf" contextRef="C_ee8b611c-368b-4b8c-a1ac-449d6289aa0e" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Waltham</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">, </span><span><ix:nonNumeric id="F_8f9e54d3-17f4-4c92-aafe-4d47c1550412" contextRef="C_ee8b611c-368b-4b8c-a1ac-449d6289aa0e" name="dei:EntityAddressStateOrProvince"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">MA</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_9268886d-497a-4e7a-a5ab-33bf683c233f" contextRef="C_ee8b611c-368b-4b8c-a1ac-449d6289aa0e" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">02451</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Address of Principal Executive Offices)</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Zip Code)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Registrant&#8217;s telephone number, including area code: </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_df43dae2-2548-4976-a814-958acffe7bac" contextRef="C_ee8b611c-368b-4b8c-a1ac-449d6289aa0e" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(781)</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_90bb8f38-b801-41cc-82d8-87ab140f80aa" contextRef="C_ee8b611c-368b-4b8c-a1ac-449d6289aa0e" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">819-0080</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Not applicable</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(Former Name or Former Address, if Changed Since Last Report)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;border-bottom:1pt solid #000000;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:2.36%;"/>
    <td style="width:97.64%;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_0b424688-293f-4b09-b0a6-fa51be15c959" contextRef="C_ee8b611c-368b-4b8c-a1ac-449d6289aa0e" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:2.34%;"/>
    <td style="width:97.66%;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_cab1f135-a8c4-4ec6-af28-cfc1c3cb295b" contextRef="C_ee8b611c-368b-4b8c-a1ac-449d6289aa0e" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:1.88%;"/>
    <td style="width:98.12%;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_3c0c62d6-2243-47c6-82e1-80e38473a4f7" contextRef="C_ee8b611c-368b-4b8c-a1ac-449d6289aa0e" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:1.9%;"/>
    <td style="width:98.1%;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_4c52c71b-98dc-427e-a049-3fd74ff5a5c1" contextRef="C_ee8b611c-368b-4b8c-a1ac-449d6289aa0e" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:51.41%;"/>
    <td style="width:1%;"/>
    <td style="width:9.142%;"/>
    <td style="width:1%;"/>
    <td style="width:37.447%;"/>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;border-bottom:1pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Title of each class</span></p></td>
    <td style="vertical-align:bottom;border-bottom:1pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;border-bottom:1pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Trading</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Symbol(s)</span></p></td>
    <td style="vertical-align:bottom;border-bottom:1pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;border-bottom:1pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Name of each exchange</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">on which registered</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_b4115ff1-b25c-49a9-9b7e-943309adb782" contextRef="C_ee8b611c-368b-4b8c-a1ac-449d6289aa0e" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Common stock, par value $0.0001 per share</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_07bc232f-c087-4ed1-9770-fdaf8fd1b331" contextRef="C_ee8b611c-368b-4b8c-a1ac-449d6289aa0e" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">IVVD</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_74d24ddf-3c61-4188-b79e-0a763f25412e" contextRef="C_ee8b611c-368b-4b8c-a1ac-449d6289aa0e" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">The Nasdaq Stock Market LLC</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Emerging growth company </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_109e4422-b049-4872-a33a-7a2be2e0d888" contextRef="C_ee8b611c-368b-4b8c-a1ac-449d6289aa0e" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5f60f15b-79c7-4513-a59c-5d5f56a9314f" contextRef="C_ee8b611c-368b-4b8c-a1ac-449d6289aa0e" name="dei:EntityExTransitionPeriod" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:10.58%;"/>
    <td style="width:89.42%;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Item 8.01.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Other Events.</span></p></td>
   </tr>
  </table>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On September 4, 2024, Invivyd, Inc. issued a press release entitled &#8220;Invivyd Doses First Participants in Phase 1 Clinical Trial of VYD2311, a Next Generation Monoclonal Antibody Candidate for COVID-19, Building on the Success of PEMGARDA&#153;.&#8221; A copy of the press release is filed herewith as Exhibit 99.1 and is incorporated by reference in this Item 8.01.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:10.58%;"/>
    <td style="width:89.42%;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Item 9.01.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Financial Statements and Exhibits.</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(d) Exhibits</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:5.88%;"/>
    <td style="width:1%;"/>
    <td style="width:93.12%;"/>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid #000000;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Exhibit<br/>No.</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid #000000;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Description</span></p></td>
   </tr>
   <tr style="height:14.4pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">99.1</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="ivvd-ex99_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Press Release, dated September 4, 2024</span></a></p></td>
   </tr>
   <tr style="height:14.4pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">104</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SIGNATURES</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.496%;"/>
    <td style="width:4.003%;"/>
    <td style="width:4.003%;"/>
    <td style="width:46.497%;"/>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">INVIVYD, INC.</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date: September 4, 2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Jill Andersen</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Jill Andersen</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chief Legal Officer and Corporate Secretary</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></div>
  <hr style="page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ivvd-ex99_1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html>
 <head>
  <title>EX-99.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',serif;min-width:fit-content;">Exhibit 99.1</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img59752938_0.jpg" alt="img59752938_0.jpg" style="width:181px;height:27px;">&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:16pt;font-family:'Aptos',serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:'Aptos',serif;min-width:fit-content;">Invivyd Doses First Participants in Phase 1 Clinical Trial of VYD2311, a Next Generation Monoclonal Antibody Candidate for COVID-19, Building on the Success of PEMGARDA</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:10.72pt;font-family:'Aptos',serif;min-width:fit-content;">&#153;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Aptos',serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Aptos',serif;min-width:fit-content;">WALTHAM, Mass., September 4, 2024 </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',serif;min-width:fit-content;">&#x2013; Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced dosing of the first participants in the Phase 1 healthy volunteer clinical trial of VYD2311, a next generation monoclonal antibody (mAb) candidate for COVID-19. VYD2311 is a mAb with high in vitro neutralization potency shown against post-Omicron COVID-19 variants tested to date.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',serif;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Aptos',serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',serif;min-width:fit-content;">The Phase 1 randomized, blinded, placebo-controlled clinical trial will evaluate escalating dosing as well as safety, tolerability, pharmacokinetics and immunogenicity of VYD2311 in healthy trial participants (</font><font><font style="white-space:pre-wrap;font-size:11pt;font-family:'Aptos',serif;min-width:fit-content;">NCT06523153</font></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',serif;min-width:fit-content;">). The Phase 1 trial is being conducted in Australia and will evaluate multiple dose levels of VYD2311 through various routes of administration, including exploration of intramuscular (IM) administration, which is designed to be more system- and patient-friendly than intravenous administration.  In addition, consistent with the company&#x2019;s overall strategy, VYD2311 was discovered via affinity maturation against more recent variants of SARS-CoV-2. The company expects preliminary data readouts from the Phase 1 trial in the fourth quarter of 2024 and anticipates additional clinical readouts from the VYD2311 program throughout 2025.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Aptos',serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',serif;min-width:fit-content;">&#x201c;We are excited that VYD2311 has potential to build on the success of PEMGARDA&#153; (pemivibart), which was granted Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration (FDA) for pre-exposure prophylaxis (PrEP) for COVID-19 for certain immunocompromised patients,&#x201d; said Marc Elia, Chairman of the Board. &#x201c;COVID-19 and its long-term health impact continue to be a global threat to every individual. Therefore, at Invivyd we are focused on developing novel therapeutics that keep pace with the viral evolution of this disease, with the mission to help protect all individuals who may benefit from greater protection than that available from vaccine boosts.&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',serif;min-width:fit-content;">   </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Aptos',serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Aptos',serif;min-width:fit-content;">About VYD2311</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',serif;min-width:fit-content;">VYD2311 is a novel monoclonal antibody (mAb) candidate being developed for COVID-19 to continue to address the urgent need for new therapeutic options for vulnerable populations, including immunocompromised people. Globally, there are millions of immunocompromised people, with an estimated 8 million in the U.S. alone, who may not adequately respond to COVID-19 vaccination, increasing their risk for severe outcomes from COVID-19.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',serif;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',serif;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',serif;min-width:fit-content;">VYD2311 was engineered from adintrevimab, Invivyd&#x2019;s investigational mAb that has a robust safety data package and demonstrated clinically meaningful results in global Phase 3 clinical trials for both the prevention and treatment of COVID-19. The pharmacokinetic profile of VYD2311 may offer the ability to deliver clinically meaningful titer levels through more patient-friendly means such as an intramuscular route of administration.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',serif;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',serif;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Aptos',serif;min-width:fit-content;">About PEMGARDA</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',serif;min-width:fit-content;"><br>PEMGARDA&#153; (pemivibart) is a half-life extended investigational monoclonal antibody (mAb). PEMGARDA was engineered from adintrevimab, Invivyd&#x2019;s investigational mAb that has a robust safety data package and provided evidence of clinical efficacy in a global Phase 2/3 clinical trial for the prevention and treatment of COVID-19. PEMGARDA has demonstrated in vitro neutralizing activity against major SARS-CoV-2 variants, including JN.1. PEMGARDA targets the SARS-CoV-2 spike protein receptor binding domain (RBD), thereby inhibiting virus attachment to the human ACE2 receptor on host cells.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Aptos',serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',serif;min-width:fit-content;">PEMGARDA (pemivibart) injection (4500 mg), for intravenous use is an investigational mAb that has not been approved, but has been authorized for emergency use by the U.S. FDA under an EUA for the pre-exposure prophylaxis (prevention) of COVID-19 in adults and adolescents (12 years of age and older weighing at least 40 kg) who have moderate-to-severe immune compromise due to certain medical conditions or receipt of certain immunosuppressive medications or treatments and are unlikely to mount an adequate immune response to COVID-19 vaccination. Recipients should not be currently infected with or have had a known recent exposure to an individual infected with SARS-CoV-2.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Aptos',serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',serif;min-width:fit-content;">PEMGARDA is not authorized for use for treatment of COVID-19 or post-exposure prophylaxis of COVID-19. Anaphylaxis has been observed with PEMGARDA and the PEMGARDA Fact Sheet for Healthcare Providers includes a boxed warning for anaphylaxis. The most common adverse events (all grades, incidence &#x2265;2%) observed in participants who have moderate-to-severe immune compromise treated with PEMGARDA included systemic and local infusion-related or hypersensitivity reactions, upper respiratory tract infection, viral infection, influenza-like illness, fatigue, headache, and nausea. For additional information, please see the PEMGARDA full product Fact Sheet for Healthcare Providers, including important safety information and boxed warning.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Aptos',serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',serif;min-width:fit-content;">To support the EUA for PEMGARDA, an immunobridging approach was used to determine if PEMGARDA may be effective for pre-exposure prophylaxis of COVID-19. Immunobridging is based on the serum virus neutralizing titer-efficacy relationships identified with other neutralizing human mAbs against SARS-CoV-2. This includes adintrevimab, the parent mAb of pemivibart, and other mAbs that were previously authorized for EUA. There are limitations of the data supporting the benefits of PEMGARDA. Evidence of clinical efficacy for other neutralizing human mAbs against SARS-CoV-2 was based on different populations and SARS-CoV-2 variants that are no longer circulating. Further, the variability associated with cell-based EC50 value determinations, along with limitations related to pharmacokinetic data and efficacy estimates for the mAbs in prior clinical trials, impact the ability to precisely estimate protective titer ranges. Additionally, certain SARS-CoV-2 viral variants may have substantially reduced susceptibility to PEMGARDA, and PEMGARDA may not be effective at preventing COVID-19 caused by these SARS-CoV-2 viral variants.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Aptos',serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',serif;min-width:fit-content;">The emergency use of PEMGARDA is only authorized for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of drugs and biological products during the COVID-19 pandemic under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. &#167; 360bbb-3(b)(1), unless the declaration is terminated or authorization revoked sooner.  PEMGARDA is authorized for use only when the combined national frequency of variants with substantially reduced susceptibility to PEMGARDA is less than or equal to 90%, based</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',serif;min-width:fit-content;"> </font></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',serif;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',serif;min-width:fit-content;">on available information including variant susceptibility to PEMGARDA and national variant frequencies.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Aptos',serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Aptos',serif;min-width:fit-content;">About Invivyd</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',serif;min-width:fit-content;"><br>Invivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, beginning with SARS-CoV-2. The company&#x2019;s proprietary INVYMAB&#153; platform approach combines state-of-the-art viral surveillance and predictive modeling with advanced antibody engineering. INVYMAB is designed to facilitate the rapid, serial generation of new monoclonal antibodies (mAbs) to address evolving viral threats. In March 2024, Invivyd received emergency use authorization (EUA) from the U.S. FDA for its first mAb in a planned series of innovative antibody candidates. Visit </font><font><font style="white-space:pre-wrap;font-size:11pt;font-family:'Aptos',serif;min-width:fit-content;">https://invivyd.com/</font></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',serif;min-width:fit-content;"> to learn more.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Aptos',serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Aptos',serif;min-width:fit-content;">Cautionary Note Regarding Forward Looking Statements</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Aptos',serif;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',serif;min-width:fit-content;">This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as &#x201c;anticipates,&#x201d; &#x201c;believes,&#x201d; &#x201c;could,&#x201d; &#x201c;expects,&#x201d; &#x201c;estimates,&#x201d; &#x201c;intends,&#x201d; &#x201c;potential,&#x201d; &#x201c;projects,&#x201d; and &#x201c;future&#x201d; or similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements include statements concerning, among other things, the company&#x2019;s ongoing research and clinical development activities, as well as future potential research and clinical development efforts; the company&#x2019;s expectation the Phase 1 clinical trial will be ongoing and allow for multiple doses of VYD2311 to be tested through various routes of administration including intramuscular administration; the expectation that an intramuscular route of administration is more system- and patient-friendly than intravenous administration; the company&#x2019;s expectation that preliminary data readouts from the Phase 1 trial will be available in the fourth quarter of 2024; the company&#x2019;s expectation that additional clinical readouts from the VYD2311 program will be available throughout 2025; the potential of VYD2311 to build on the success of PEMGARDA&#153; (pemivibart); the company&#x2019;s expectation that COVID-19 and its long-term health impact continue to be a global threat to every individual; the company&#x2019;s focus on developing novel therapeutics that keep pace with the viral evolution of COVID-19, with the mission to help protect all individuals who may benefit from greater protection than that available from vaccine boosts; the ability of VYD2311 to deliver clinically meaningful titer levels through more patient-friendly means such as intramuscular or subcutaneous routes of administration; the company&#x2019;s devotion to delivering protection from serious viral infectious diseases, beginning with SARS-CoV-2; the design of the company&#x2019;s INVYMAB platform approach to facilitate the rapid, serial generation of new mAbs to address evolving viral threats; the potential of PEMGARDA as a mAb for pre-exposure prophylaxis (prevention) of COVID-19 in adults and adolescents who have moderate-to-severe immune compromise; the ongoing </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',serif;font-style:italic;min-width:fit-content;">in vitro</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',serif;min-width:fit-content;"> neutralizing activity of PEMGARDA against major SARS-CoV-2 variants; and other statements that are not historical fact. The company may not actually achieve the plans, intentions or expectations disclosed in the company&#x2019;s forward-looking statements and you should not place undue reliance on the company&#x2019;s forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause the company&#x2019;s actual results to differ materially from the results described in or implied by the forward-looking statements, including, without limitation: the timing and progress of the company&#x2019;s discovery, preclinical and clinical development activities; the risk that results of nonclinical studies or clinical trials may not be predictive of future results, and interim data are subject to further analysis; unexpected safety or efficacy data observed during preclinical studies or clinical trials; the predictability of clinical success of the company&#x2019;s product candidates based on neutralizing</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',serif;min-width:fit-content;"> </font></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',serif;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',serif;min-width:fit-content;">activity in nonclinical studies; potential variability in neutralizing activity of product candidates tested in different assays, such as pseudovirus assays and authentic assays; the company&#x2019;s reliance on third parties with respect to virus assay creation and product candidate testing and with respect to its clinical trials; variability of results in models used to predict activity against SARS-CoV-2 variants; whether VYD2311, pemivibart or any other product candidate is able to demonstrate and sustain neutralizing activity against major SARS-CoV-2 variants, particularly in the face of viral evolution; how long the EUA granted by the FDA for PEMGARDA will remain in effect and whether the EUA is revoked or revised by the FDA;  the company&#x2019;s ability to build and maintain sales, marketing and distribution capabilities to successfully commercialize PEMGARDA; uncertainties related to the regulatory authorization or approval process, and available development and regulatory pathways for authorization or approval of the company&#x2019;s product candidates; the ability to maintain a continued acceptable safety, tolerability and efficacy profile of any product candidate following regulatory authorization or approval; changes in the regulatory environment; changes in expected or existing competition; the complexities of manufacturing mAb therapies; the company&#x2019;s ability to leverage its INVYMAB platform approach to facilitate the rapid, serial generation of new mAbs to address evolving viral threats; any legal proceedings or investigations relating to the company; the company&#x2019;s ability to continue as a going concern; and whether the company has adequate funding to meet future operating expenses and capital expenditure requirements. Other factors that may cause the company&#x2019;s actual results to differ materially from those expressed or implied in the forward-looking statements in this press release are described under the heading &#x201c;Risk Factors&#x201d; in the company&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2023 and the company&#x2019;s Quarterly Report on Form 10-Q for the quarter ended June 30, 2024, each filed with the Securities and Exchange Commission (SEC), and in the company&#x2019;s other filings with the SEC, and in its future reports to be filed with the SEC and available at </font><font style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:'Aptos',serif;min-width:fit-content;">www.sec.gov</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',serif;min-width:fit-content;">. Forward-looking statements contained in this press release are made as of this date, and Invivyd undertakes no duty to update such information whether as a result of new information, future events or otherwise, except as required under applicable law.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',serif;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',serif;min-width:fit-content;">This press release contains hyperlinks to information that is not deemed to be incorporated by reference in this press release.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',serif;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Aptos',serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Aptos',serif;min-width:fit-content;">Contacts:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Aptos',serif;min-width:fit-content;">Media Relations</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',serif;min-width:fit-content;">(781) 208-0160</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',serif;min-width:fit-content;">media@invivyd.com</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Aptos',serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Aptos',serif;min-width:fit-content;">Investor Relations</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',serif;min-width:fit-content;">(781) 208-0160</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',serif;min-width:fit-content;">investors@invivyd.com</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Aptos',serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>img59752938_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img59752938_0.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  (! 0$! 0(! 0$" @(" @0# @("
M @4$! ,$!@4&!@8%!@8&!PD(!@<)!P8&" L("0H*"@H*!@@+# L*# D*"@K_
MVP!# 0(" @(" @4# P4*!P8'"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@K_P  1"  \ 9H# 2(  A$! Q$!_\0
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MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#X1_X>4?\
M!1;_ */Z^-7_ (=35_\ Y(K]TO\ @V/^-_QH^/?[!GB[QC\=/B]XH\::O;?%
MV_L[?5/%GB"YU*YBMETO2G6%9+AW98P\DC! <!G8XRQS_.'7]"G_  :;?\HZ
M?&G_ &6K4?\ TT:/7ZAQ7AZ%/*&XP2=ULDCGI_$?J!1117Y>=!Y%_P % _$O
MB/P9^P7\;O&'@_7[[2=6TGX1>)+S2]4TVZ>"YL[F+2[AXYHI$(:.1'565U(*
MD @@BOY<O^'E'_!1;_H_KXU?^'4U?_Y(K^H#_@I/_P HZ?C[_P!D5\5?^FBZ
MK^16OT+@VC1J86JYQ3]Y;I/H8U>A]I?\$_O^"UW[8W[,7[57AGXG?'/]I7XD
M^/O _P!H-EXQ\,^(_%UUJB3:?+A9)88[N1U6XB.V:-E,;,8_++K'+(#_ $Z^
M&O$OAWQGX<T_QAX/U^RU;2=6LHKS2]4TVZ2>WO+>5 \<T4B$K)&Z,&5E)# @
M@D&OXU?B+\./%WPK\10^%_&NE_9+JXT;3=6M8_.CD\RRO[*"^LYLHS >9;7,
M,FTG<N_:P5@RC]S/^#7W_@I%>?%SX6:C^P+\7O$K7'B#P-9_;O %U?74DDU[
MHA;;+9C*8'V20Q[ 9"QAN%1$6.U)I\5933J898S#Q7N[VZQ>ST[?D^R"G+6S
M/UKKY%_X+O?$KXC?"'_@E/\ %3XB?";Q]K7A?Q!I_P#8?]GZ[X=U6:RO+;S-
M=T^)_+FA973=&[H<$95V!X)%?75?%7_!Q%_RAU^,'_<O_P#J0Z;7Q65I2S.@
MG_/'_P!*1I+X6?SU?\/*/^"BW_1_7QJ_\.IJ_P#\D5_4Y^Q1K^N^*OV-?A)X
MH\4:U=ZEJ>I?#'0;K4=1U"X::>ZGDTZ!Y)9)')9W9B69F))))))-?Q\U_7Y^
MP3_R8Q\%_P#LD_AS_P!-EO7V7&=&C3P]'DBEJ]DET,Z74]8KPG_@IG\,_C3\
M6/V$OB5X6_9S^(GB?POXZ@\//J?A;4_!UU<0ZE+=V;K=K90M;RQ.&NA";7(8
MX%QNVOC:?=J*^#HU)4:T:BW33U\M38_D5_X>4?\ !1;_ */Z^-7_ (=35_\
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MA7IU?CF*PN(P6(G0KQ<9Q;33W370_*:]"MA:TJ56+C*+LT^C05Y[^T_^T_\
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MY3H%4!],!)8X"?I.)?\ 8/#?(M)<MO\ MZ6_W7;^1@O?J'ZY4445^5G0%?S
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M\00G[#/=6<4[P?.P;Y&D*\@'Y>0#7\A-;%K\0/&]E;1V=IXIOHXH8PD<:W!
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M#^RW_P %.O' T_/]D_$3;XVTCS+KS9/]/DE^UA_E4)_IT5YL3G$7EY))-?U
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M(^[/$/B'0?"6@7WBKQ5K=GIFEZ99R7>I:EJ%RL-O:6\:EY)9)'(5$5069F(
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M&MT/ZZO^";'_ "CI^ 7_ &17PK_Z:+6O:J\4_P"":YS_ ,$Z/@"?^J*>%?\
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MOKN"_P#D:3_P/_TJ)G5^$]K_ .#3;_E(MXT_[(KJ/_IWT>OZ%*_GK_X--O\
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7BBOSK$XBMBZ\JU5WD]W_ %^!T+30_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>ivvd-20240904.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2024-09-03T17:33:41.6365+00:00 -->
<!-- Copyright (c) 2024 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://invivyd.com/20240904" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:ivvd="http://invivyd.com/20240904" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" namespace="http://xbrl.sec.gov/dei/2024"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" namespace="http://fasb.org/us-gaap/2024"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://invivyd.com/20240904/taxonomy/role/Role_DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:roleRef roleURI="http://invivyd.com/20240904/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:href="ivvd-20240904.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://invivyd.com/20240904/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="50.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="51.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="52.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="53.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="54.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="55.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="56.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="57.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="58.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="59.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="60.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="61.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="62.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="63.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="64.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="65.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="66.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="67.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="68.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="69.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="70.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="71.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="72.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>6
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140014485241680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Sep. 04, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001832038<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep.  04,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Invivyd, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40703<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">85-1403134<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1601 Trapelo Road<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 178<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Waltham<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02451<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(781)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">819-0080<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common stock, par value $0.0001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">IVVD<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>7
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M.(/I:2O \Y64YJ-@#_W5-YO1OU!+ P04    " !%.219GZ ;\+$"  #B#
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M#ZP+V.Q _G@>F*FX3YI"5S%NV G&D3S'$)C%^(QF&5*=##[Q_F"G)$WS/(X
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MTZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0
M   ( $4Y)%D<.&7J/P$  #P"   /    >&PO=V]R:V)O;VLN>&ULC5'+;L)
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MPNZ_/[&\UDX:?^:+X3]>?P%02P$"% ,4    " !%.219!T%-8H$   "Q
M$               @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    (
M $4Y)%G*ARYD[@   "L"   1              "  :\   !D;V-0<F]P<R]C
M;W)E+GAM;%!+ 0(4 Q0    ( $4Y)%F97)PC$ 8  )PG   3
M  "  <P!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ 13DD6=A
MQX)X!   OQ$  !@              ("!#0@  'AL+W=O<FMS:&5E=',O<VAE
M970Q+GAM;%!+ 0(4 Q0    ( $4Y)%F?H!OPL0(  .(,   -
M  "  ;L,  !X;"]S='EL97,N>&UL4$L! A0#%     @ 13DD69>*NQS
M$P(   L              ( !EP\  %]R96QS+RYR96QS4$L! A0#%     @
M13DD61PX9>H_ 0  / (   \              ( !@!   'AL+W=O<FMB;V]K
M+GAM;%!+ 0(4 Q0    ( $4Y)%DD'INBK0   /@!   :              "
M >P1  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( $4Y
M)%EED'F2&0$  ,\#   3              "  =$2  !;0V]N=&5N=%]4>7!E
<<UTN>&UL4$L%!@     )  D /@(  !L4      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.2.u1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="ivvd-20240904.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://invivyd.com/20240904/taxonomy/role/Role_DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="ivvd-20240904.htm">ivvd-20240904.htm</File>
    <File>ivvd-20240904.xsd</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>13
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ivvd-20240904.htm": {
   "nsprefix": "ivvd",
   "nsuri": "http://invivyd.com/20240904",
   "dts": {
    "inline": {
     "local": [
      "ivvd-20240904.htm"
     ]
    },
    "schema": {
     "local": [
      "ivvd-20240904.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    }
   },
   "keyStandard": 24,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 25,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 24
   },
   "report": {
    "R1": {
     "role": "http://invivyd.com/20240904/taxonomy/role/Role_DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_ee8b611c-368b-4b8c-a1ac-449d6289aa0e",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ivvd-20240904.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ee8b611c-368b-4b8c-a1ac-449d6289aa0e",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ivvd-20240904.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://invivyd.com/20240904/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://invivyd.com/20240904/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover [Abstract]",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://invivyd.com/20240904/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://invivyd.com/20240904/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://invivyd.com/20240904/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://invivyd.com/20240904/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line Two",
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://invivyd.com/20240904/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://invivyd.com/20240904/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://invivyd.com/20240904/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://invivyd.com/20240904/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://invivyd.com/20240904/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://invivyd.com/20240904/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Ex Transition Period",
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://invivyd.com/20240904/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://invivyd.com/20240904/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation State Country Code",
        "label": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://invivyd.com/20240904/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://invivyd.com/20240904/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://invivyd.com/20240904/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://invivyd.com/20240904/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre Commencement Issuer Tender Offer",
        "label": "Pre Commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://invivyd.com/20240904/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre Commencement Tender Offer",
        "label": "Pre Commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://invivyd.com/20240904/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security 12b Title",
        "label": "Security 12b Title",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://invivyd.com/20240904/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://invivyd.com/20240904/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://invivyd.com/20240904/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://invivyd.com/20240904/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>14
<FILENAME>0000950170-24-103100-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-24-103100-xbrl.zip
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MX!U2K6#L.!91-$0?9<SB0+((=<I!]V"600T=1A$Z5ZTR="XRD5X)7BOZ[.:
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M8"L'2^@8V.-V@%WN,LNT72K\<#6:_R'GJ<BRT9_/,A9DC1* - R"+J")B!+
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MUWT:9*,(<$V-A8Q,H]4DC0_I^UPK'S&YWB,P1>/UIJS8SI/OTPJ;27FNJ*F
MD6&LQ6S_/@0+78 I ZFV)B-'5D"7YB_V(GRC#0AUS0:/K.#63L>\63SS^$R.
MPJ!=XIDWMD4Y!76083[3")C*=$ENXXTH#OT&\4M3;?N0GRL"F:;&0D:FT>IG
M"O=AFVD%VVI!IA>DBH_#'&39$M7,Z$%B(*$0<(U-MZ 8"QD#KYSTW8?_7"&0
M-3;>!&0+O6XV^P"AT<<5>-&:O\V.P11DU8JZN?J#OB\R[;9>&WO;IGMY&#9+
MM5[A /WG1>&;#\.'L #9!:]<A'&(42S7"S+%(-=\) :A9MCRLO;D "W"E8%,
M6Y.1(WN@-4MH#L ]TPQDU<=F%+)OS_8:HKWF,-.D#5/TY@L4]D&,3(,MKH7:
MA^)4%TB5&7",?9&C/4!?47GAFD=]436[K*D]EW!]PD*P1>QD0/+B4TKFM7O%
M1-UDI\59NM5MYHS8:;N9;$W]XB7[9FDVH<F&J-;XV(=>O35-Z5BJ!3$V#5%N
M6!/(RZM(&L.Y:AN;DO#2V@N;)B@WMPG8Y34+C6&[O.5-R75AOM\F?-5&.(&Y
M-%EN$ZAN>YP JYQSM@I8NVEN UD]:=L8;U9MI:L;.P;63:C<8%=T[?*LH$WH
MRFUW G)Y5LTFU/K-> )WS814$\84U1:]XKA2FL.Q";QRXYY KI_]L#_"Z+?S
MR0.,9LJ@09ZOW>2G\7]U9MU^BZBW_LFMH<A"VP=>N2&PX$W:O*U],\K;!&7L
MA6RG?< UFP=E]%490JN?=8HMA9NONF)FS290W49# 5:9G]H^"VDKS<3BM-^+
MIR05C[)2I;;>XA"H_'2E8O5R7L[P(4N-/)RFP>>]-/QXI :>]7(4AX!4Q04U
M$]3?SQ?[?D2 E2,":G.?)< 6C_"J3;;L -;8N44U>4X=5/-'>^TRY:!#:^DT
MO/K)-QU@*Z<Z_A^?P]'60Y8:?L+;D1W]=<3G0#7X%,)&'DIW!*>\[9 FVVV%
MXY&?^+:=8SA(RF;A4:;/\9]"M,&VXXJ!PM<\H:R?7W1.S_F/+2R8 =Q7+CHL
M$$PBAH0L.&8^)C,;V&! 87";<;#S<JF&\Z%)).2\G/7:RHN<NQ!T]-M.1R%O
M(G@9M)47=:I&T'+2;EIJTD."I=-VL[2=@Q*4G+6;$FWN2_#SKMW\*--L@IOW
MW[DI9?4$-W_[SDTAB2B8:7D K,M:YO2\:VT<7)4A%>2T-BJ6\[&"CM8&P^5<
ML*"DM8&P)@<M>&EMZ*M*>PM26AO\5B7;!3FMC7SK4_N"HM8&P.4I!$%):^/>
MPM2%X*.UT:YZUB2GY7W+HUS-3(U@I[5AKGY:2%!C).3-5](65ZP* ;'0-LQ^
M:36[_<$M_*9N?F/KEW>S.]GO %_^#U!+ P04    " !%.219[*8E9^05  !R
M<0  #P   &EV=F0M97@Y.5\Q+FAT;>U=:W<;M]'^WE^!-SU]*YU#TKI$CBVZ
M.:\BRZG;V'%MQVD_O0?<!4E$NXL-L$N*^?5]9@#LA:1DR3?%L7K22-H+@!G,
M/'/%YM&\RK-O_R0>S95,\5,\JG25J6_/_CU\^'"T_^B>_Q,/W M//)J8="5<
MM<K4W[[*I9WIXEC(NC+_H_/2V$H6U;B4::J+V;%X4%Z,O^)A4[V(+X6[P\J4
MQWNC(UV,<UT,YTK/YM7Q/OZ<F(NAT[_1"!-C4V6'N()Q'I5QB*DI*GI$'>_O
ME=78+\,/..9[4YGK;'7\6N?*B>=J*5Z:7!;QP8FI*I/CV4I=5$.9Z5EQ;&EZ
MFH3>C_,D)C/V^,][_+_Q<JXK-72E3-1Q:=5P:67IIUOZQ4],EH[7UM9=SE]/
MRLJXOPZ<LGK*5"]U6LV/I[H:)GA.%;2"LXNYGNA*^ V@][]]=*_$_\%#YN4G
M9\/EA/O)#]Z)SO_]\_[]O7&'PH]-6Z:F3)K.9\+9Y&]?X9>CA]\<'3P\?/#_
M>Z-?RME70F;5UNN1$TS'_H-]"':0V(-O6,@C-9^.C)OLT/W/:X<^H Z^&^5/
MBX5>K%+QV#BL_8FVKA(OI*UTHDL@G!.Z$"_FTBFQ+TXS7>A$9N*UU?BWF8HW
M_WE\<+B_/Q 29%]4XGM5*"LK;0KQS!0FR4R!!T^*2C.8GLHBU:FLE)@:*TY_
M?//T\7#_X4!\5^N,D%+@O6JNQ*LZ291S-,.+LV??G[Q\?!+WYGT9ME!$F\S"
M/KBZ5+:'9*-OWEG)CPYO6X3>IAW[7ZQVO!OE/Y_\\/KO)\\&XIET;C00KU19
MJ7RBK/AZ( [V#KX6[R.7[[<G%P=[^X=C$11X@%^2D=AY+ETJ?ST63]^\>;Q+
M>CG1IIQ+FV/ZFB5?)":':J]$JA:F4JFH#'[--#2#5+"TN)BP"D^MR04MP]1.
M++3%N[J8\DU<2+53P 4WP "I7 E9%*8N$@R8&L?*/&5EGC*FE&N80G<BKL#A
MRJKY2BQ,5H,^<#>)2%-M09J"D&;6(DW>(HV,2+.3GTQV1;(5;T9Q,*$=AL.3
M8JFKN9A#<&AI"UU9@UGJ"A3KW_PD);A2)/ 'YV99"#F3NB"JC*N&/^8ZL7@D
MCB\6$JLF.BOE(H.QB-%MR8JX0Z7;1J7W(?1U1U4L)-KD& P*/X&2I/1+F6'"
MB>%7K,DRB-R: BUUE@FUD%E-RJ <[D"LH:-!5:432X5'\-/)J:I6I-09%&RB
M,TU_!0@QY[I0T&/H39$*G>=U8:")4.QJU=%2TJ*HU'X!/?7?Z2K"IQ"5YZ>O
M]^X?865'AXV\W(XJ[HY$=SL]<P!#$T7;@.?2.B'(  -/:L< ))G7_1W,ZZS2
M9:9H_Y3(U$)EKLO_:FY-#30C)"*LQE_ (GI"IEB:II$)U@:8*,EJ]KW410GZ
M/=KA00U9DGGMDCJ35NP\?;:[\2Y8E,QI]:ER4!"/=!.LSE@EW K8EP]Y\25>
M4,0JBQ]I!J&8R\+/L% %+; _]$C F@F*GOU$X(O#30SAD9J,1[!BW@X^'(,X
M&# ))O$@:@:AC=Q82K96"3V!12Z(I=,IYH/0YK*J ]$1U'GY5B4T70/EX,BK
MDY>OAJ?FS?# ;V*THV <;**#Y805!1G2K@CO)<:0*1COO"&M-O?=F\&IJ2V(
M^K6&CL#V82;V+(AQ9,](:VCS(CO(@D?MWIPAT@PS/L/^14G 0S3JT>C.%'S.
MIL!+>S+^60D)(547 %Y2N[FLFIV'B'EOI2(9(XVDZ"J&5FXSM/*1B]@I5:X7
M>@(IW(VZ39H#,2IHDK-<V1G[0#]!AD_J:FYL](YVSGXZV163%4_QT^C52#PQ
M)F41?FSKF3CIJ;?8>?(8CY-/1JR!_AA7@QS(;#E?9?("D++SPIZ]V.WY;?Q'
M@O@-:AIL#ZD@)!^>: ,R;N"9E(YARG0*S]TFX@PP.A"G<ZEAQ8KHF7YGI$U'
M(C*UF8=M&Y0*/N5L")7,@S'#I-C/BN (QK-6 >ZDF&5F0KR>0Q\KN@I !@C
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M%U!+ 0(4 Q0    ( $4Y)%F3K) G<!,  ##%   1              "  0
M  !I=G9D+3(P,C0P.3 T+FAT;5!+ 0(4 Q0    ( $4Y)%FGWLF!HPD  #U]
M   1              "  9\3  !I=G9D+3(P,C0P.3 T+GAS9%!+ 0(4 Q0
M   ( $4Y)%GLIB5GY!4  ')Q   /              "  7$=  !I=G9D+65X
>.3E?,2YH=&U02P4&      ,  P"[    @C,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>ivvd-20240904_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="ivvd-20240904.xsd" xlink:type="simple"/>
    <context id="C_ee8b611c-368b-4b8c-a1ac-449d6289aa0e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832038</identifier>
        </entity>
        <period>
            <startDate>2024-09-04</startDate>
            <endDate>2024-09-04</endDate>
        </period>
    </context>
    <dei:AmendmentFlag
      contextRef="C_ee8b611c-368b-4b8c-a1ac-449d6289aa0e"
      id="F_cf9258cb-0d80-48de-a3a4-1de84b58c544">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="C_ee8b611c-368b-4b8c-a1ac-449d6289aa0e"
      id="F_8623cbe1-96f9-474f-9f72-079429d958e3">0001832038</dei:EntityCentralIndexKey>
    <dei:DocumentType
      contextRef="C_ee8b611c-368b-4b8c-a1ac-449d6289aa0e"
      id="F_143f54b2-1deb-4552-a6a4-a3e61dd4602e">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="C_ee8b611c-368b-4b8c-a1ac-449d6289aa0e"
      id="F_c3a64289-26a5-4713-833e-432f94fe9639">2024-09-04</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="C_ee8b611c-368b-4b8c-a1ac-449d6289aa0e"
      id="F_757c114b-1823-41a1-8588-3e7440648c09">Invivyd, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_ee8b611c-368b-4b8c-a1ac-449d6289aa0e"
      id="F_1f0054b3-ff26-4b0f-9ee1-735b33f484c9">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="C_ee8b611c-368b-4b8c-a1ac-449d6289aa0e"
      id="F_96edda8a-8f73-4e57-b549-ce8bf2a90843">001-40703</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_ee8b611c-368b-4b8c-a1ac-449d6289aa0e"
      id="F_7ba1cddb-0dd9-4ad4-8a40-e242f9e45c6c">85-1403134</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_ee8b611c-368b-4b8c-a1ac-449d6289aa0e"
      id="F_a45ec0d3-c526-4f70-9d5c-8d8a32584ebf">1601 Trapelo Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_ee8b611c-368b-4b8c-a1ac-449d6289aa0e"
      id="F_97225d7c-5297-441c-9f2b-e0122b7c1b60">Suite 178</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_ee8b611c-368b-4b8c-a1ac-449d6289aa0e"
      id="F_1b00c894-2915-410e-9f53-43e248a829cf">Waltham</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_ee8b611c-368b-4b8c-a1ac-449d6289aa0e"
      id="F_8f9e54d3-17f4-4c92-aafe-4d47c1550412">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_ee8b611c-368b-4b8c-a1ac-449d6289aa0e"
      id="F_9268886d-497a-4e7a-a5ab-33bf683c233f">02451</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_ee8b611c-368b-4b8c-a1ac-449d6289aa0e"
      id="F_df43dae2-2548-4976-a814-958acffe7bac">(781)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_ee8b611c-368b-4b8c-a1ac-449d6289aa0e"
      id="F_90bb8f38-b801-41cc-82d8-87ab140f80aa">819-0080</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="C_ee8b611c-368b-4b8c-a1ac-449d6289aa0e"
      id="F_0b424688-293f-4b09-b0a6-fa51be15c959">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="C_ee8b611c-368b-4b8c-a1ac-449d6289aa0e"
      id="F_cab1f135-a8c4-4ec6-af28-cfc1c3cb295b">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="C_ee8b611c-368b-4b8c-a1ac-449d6289aa0e"
      id="F_3c0c62d6-2243-47c6-82e1-80e38473a4f7">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="C_ee8b611c-368b-4b8c-a1ac-449d6289aa0e"
      id="F_4c52c71b-98dc-427e-a049-3fd74ff5a5c1">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="C_ee8b611c-368b-4b8c-a1ac-449d6289aa0e"
      id="F_b4115ff1-b25c-49a9-9b7e-943309adb782">Common stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_ee8b611c-368b-4b8c-a1ac-449d6289aa0e"
      id="F_07bc232f-c087-4ed1-9770-fdaf8fd1b331">IVVD</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_ee8b611c-368b-4b8c-a1ac-449d6289aa0e"
      id="F_74d24ddf-3c61-4188-b79e-0a763f25412e">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_ee8b611c-368b-4b8c-a1ac-449d6289aa0e"
      id="F_109e4422-b049-4872-a33a-7a2be2e0d888">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="C_ee8b611c-368b-4b8c-a1ac-449d6289aa0e"
      id="F_5f60f15b-79c7-4513-a59c-5d5f56a9314f">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
